| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14622416.5.8.1049 |
| P698 | PubMed publication ID | 15584876 |
| P50 | author | Ramón Cacabelos | Q66809646 |
| P2860 | cites work | Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease | Q24672501 |
| Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts | Q24675729 | ||
| NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant | Q24791908 | ||
| Alzheimer Disease and Oxidative Stress | Q24801475 | ||
| Global mapping of the yeast genetic interaction network | Q27934987 | ||
| Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins | Q28168105 | ||
| Alzheimer's disease: the cholesterol connection | Q28186482 | ||
| Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism | Q28203757 | ||
| Deciphering the genetic basis of Alzheimer's disease | Q28216056 | ||
| Chemogenomics: an emerging strategy for rapid target and drug discovery | Q28260664 | ||
| Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators | Q28263736 | ||
| Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12 | Q28586910 | ||
| Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia | Q29397661 | ||
| Rational siRNA design for RNA interference | Q29614450 | ||
| Neurovascular regulation in the normal brain and in Alzheimer's disease | Q29619659 | ||
| A Position Paper: Based on Observational Data Indicating an Increased Rate of Altered Blood Chemistry Requiring Withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT) | Q30880135 | ||
| Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics | Q30908064 | ||
| Proteomic identification of nitrated proteins in Alzheimer's disease brain | Q31144652 | ||
| Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms | Q44801302 | ||
| Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism | Q44801726 | ||
| An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease | Q44809299 | ||
| Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain | Q44810166 | ||
| Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia | Q44815352 | ||
| Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. | Q44820147 | ||
| Homocysteine and methylenetetrahydrofolate reductase polymorphism in Alzheimer's disease. | Q44836998 | ||
| Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways | Q44899645 | ||
| Cholesterol and APOE genotype interact to influence Alzheimer disease progression | Q44907918 | ||
| Alzheimer disease risk and genetic variation in ACE: a meta-analysis | Q46122130 | ||
| Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans | Q46639824 | ||
| A polymorphism in the angiotensin 1-converting enzyme gene is associated with damage to cerebral cortical white matter in Alzheimer's disease. | Q47293922 | ||
| Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline | Q47300836 | ||
| Abeta(1-28) fragment of the amyloid peptide predominantly adopts a polyproline II conformation in an acidic solution | Q47412871 | ||
| Inflammatory proteins in plasma and the risk of dementia: the rotterdam study | Q47591273 | ||
| Gene regulatory network growth by duplication | Q47610427 | ||
| ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease | Q47754186 | ||
| Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease | Q47884196 | ||
| Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. | Q48032645 | ||
| Brain tissue microarrays in dementia research: white matter microvascular pathology in Alzheimer's disease | Q48095621 | ||
| Proteomic identification of a novel protein regulated in CA1 and CA3 hippocampal regions during intermittent hypoxia | Q48257216 | ||
| Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model | Q48381823 | ||
| Caloric intake and the risk of Alzheimer disease | Q48520005 | ||
| Genetic influences on memory performance in familial Alzheimer disease. | Q51051439 | ||
| Low blood pressure and the risk of dementia in very old individuals. | Q51944569 | ||
| Neuroanatomy: brain asymmetry and long-term memory. | Q52002701 | ||
| Transcobalamin polymorphism and serum holo-transcobalamin in relation to Alzheimer's disease. | Q52552984 | ||
| Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. | Q53229484 | ||
| Anti-apoptotic proteins are oxidized by Abeta25-35 in Alzheimer's fibroblasts. | Q53253568 | ||
| Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. | Q53259393 | ||
| APOE genotype-specific differences in human and mouse macrophage nitric oxide production. | Q53259768 | ||
| Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. | Q53261918 | ||
| Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD. | Q53261921 | ||
| Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral beta amyloid deposits. | Q53363033 | ||
| Increased risk of type 2 diabetes in Alzheimer disease | Q44745172 | ||
| Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration | Q44748602 | ||
| Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins | Q44801299 | ||
| Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation | Q33193152 | ||
| Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease | Q33920923 | ||
| Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. | Q33921362 | ||
| Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. | Q34148953 | ||
| Intelligence: genetics, genes, and genomics | Q34289169 | ||
| Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease | Q34306374 | ||
| siRNAs: applications in functional genomics and potential as therapeutics | Q34310668 | ||
| Genomics. Beyond nature and nurture | Q34314017 | ||
| The fine-scale structure of recombination rate variation in the human genome | Q34315919 | ||
| Neurogenomics: at the intersection of neurobiology and genome sciences | Q34317086 | ||
| The role of hyperglycemia in acute stroke | Q34329938 | ||
| Histamine function in brain disorders | Q34407502 | ||
| Statins and the risk of dementia | Q34511970 | ||
| Alzheimer disease as a vascular disorder: nosological evidence | Q34589057 | ||
| Statins in the prevention and treatment of Alzheimer disease | Q34647906 | ||
| Alzheimer disease therapy: can the amyloid cascade be halted? | Q34828328 | ||
| Pharmacogenomics in Alzheimer's disease | Q34947333 | ||
| Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death | Q34976924 | ||
| Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics | Q34988116 | ||
| Pharmacogenomics for the treatment of dementia | Q35009345 | ||
| Epidemiology of neurodegeneration | Q35062651 | ||
| Drugs targeting Alzheimer's disease: some things old and some things new. | Q35072933 | ||
| Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease | Q35092287 | ||
| The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol | Q35096114 | ||
| Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein | Q35097358 | ||
| The application of functional genomics to Alzheimer's disease | Q35207554 | ||
| Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration | Q35209671 | ||
| Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease | Q35480015 | ||
| Cerebrometabolic abnormalities in Alzheimer's disease | Q35540355 | ||
| Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications | Q35540359 | ||
| Comparison between Alzheimer's disease and vascular dementia: Implications for treatment | Q35540384 | ||
| cDNA microarray and proteomic approaches in the study of brain diseases: focus on schizophrenia and Alzheimer's disease | Q35556114 | ||
| Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease | Q35557675 | ||
| The role of cardiovascular risk factors in Alzheimer's disease | Q35618918 | ||
| Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease | Q35625434 | ||
| Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins | Q35636331 | ||
| The role of cholesterol and statins in Alzheimer's disease | Q35638053 | ||
| Anti-Abeta: The good, the bad, and the unforeseen | Q35638452 | ||
| Towards therapy using RNA interference | Q35676906 | ||
| Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity | Q35678432 | ||
| Imaging Alzheimer's disease: clinical applications | Q35692950 | ||
| Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography | Q35692953 | ||
| Alzheimer disease: operating characteristics of PET--a meta-analysis | Q35739933 | ||
| Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge | Q35753298 | ||
| Progress in the use of microarray technology to study the neurobiology of disease | Q35758811 | ||
| Proteomics in postgenomic neuroscience: the end of the beginning. | Q35758816 | ||
| The microglial phagocytic role with specific plaque types in the Alzheimer disease brain | Q35789675 | ||
| Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component | Q35841700 | ||
| Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. | Q35843366 | ||
| Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles | Q37069801 | ||
| Genomics of the periinfarction cortex after focal cerebral ischemia | Q38352866 | ||
| Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function | Q38422040 | ||
| Imaging cerebral atrophy: normal ageing to Alzheimer's disease | Q40518545 | ||
| Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid β Peptide Secretion | Q40646962 | ||
| Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD. | Q42525989 | ||
| Microglial activation by uptake of fDNA via a scavenger receptor. | Q42856083 | ||
| Cholesterol and neuropathologic markers of AD: a population-based autopsy study | Q43775110 | ||
| Vascular disease and cognitive function in older men in the Caerphilly cohort | Q43897088 | ||
| Serum lipoprotein levels, statin use, and cognitive function in older women | Q43915654 | ||
| Sex differences in learning in chimpanzees | Q43948849 | ||
| Proteomic analysis of protein oxidation in Alzheimer's disease brain | Q44175307 | ||
| Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue | Q44175709 | ||
| Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation | Q44182830 | ||
| APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress | Q44188924 | ||
| Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease | Q44282764 | ||
| Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques | Q44306302 | ||
| ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease | Q44324469 | ||
| Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein | Q44417421 | ||
| Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study | Q44438334 | ||
| Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice | Q44529068 | ||
| Association of the C766T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer's disease | Q44536830 | ||
| Combination of serum markers related to several mechanisms in Alzheimer's disease | Q44555806 | ||
| Inhibition of energy metabolism down-regulates the Alzheimer related presenilin 2 gene. | Q44561231 | ||
| Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease) | Q44658155 | ||
| The regulatory region polymorphisms of the MTHFR gene are not associated with Alzheimer's disease | Q44739302 | ||
| Medical comorbidity in black and white patients with Alzheimer's disease | Q44744318 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 1049-1105 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia | |
| P478 | volume | 5 |
| Q53275640 | Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia. |
| Q48708023 | Auricular vagus somatosensory evoked potentials in vascular dementia |
| Q34965949 | Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics |
| Q53314216 | Genetic evidence that vascular dementia is related to Alzheimer's disease: genetic association between tau polymorphism and vascular dementia in the Chinese population |
| Q30413222 | Meditation as a therapeutic intervention for adults at risk for Alzheimer's disease - potential benefits and underlying mechanisms |
| Q37592250 | Pharmacogenomics and therapeutic strategies for dementia |
| Q37205951 | Pharmacogenomics and treatment for dementia induced by Alzheimer's disease |
Search more.